Glenmark Pharmaceuticals receives ANDA approval for acetaminophen and ibuprofen tablets

Glenmark Pharmaceuticals Ltd. has received final approval from the United States Food & Drug Administration (USFDA) for Acetaminophen and Ibuprofen tablets, 250 mg/125 mg (OTC).

Glenmark Pharmaceuticals Ltd. has received final approval from the United States Food & Drug Administration (USFDA) for Acetaminophen and Ibuprofen tablets, 250 mg/125 mg (OTC).

The tablets were determined by the FDA to be bioequivalent1 to Advil®2 Dual Action with Acetaminophen Tablets, 250 mg/125 mg (OTC), of Haleon US Holdings, LLC.

Glenmark’s tablets will be distributed in the US by Glenmark Therapeutics Inc., USA.

Also Read: Indian shares set to open higher, tracking Asian peersGlenmark’s current portfolio consists of 195 products authorised for distribution in the US and 52 ANDA’s pending approval with the USFDA. In addition to these internal filings, the company has been exploring external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

The stock traded at ₹1,086.45 on the NSE, up 0.66 per cent as of 9.32 am.

Like (0)
Previous April 28, 2024 12:42 pm
Next April 29, 2024 4:07 pm

Related posts

  • What does GPT4o mean? OpenAI plus Apple, AI mobile phones are unstoppable!

    What does GPT 4o mean? OpenAI plus Apple, AI mobile phones are unstoppable! Hard AI Jim Fan, senior research scientist at NVIDIA: This may become an AI product with 1 billion users from the beginning. OpenAI is to Apple similar to FSD for smartphones

    stock options May 14, 2024
  • European stocks opened broadly lower, with the Stoxx Europe 50 index down 0.34%.

    Germany\’s DAX index fell 0.12%, France\’s CAC40 index fell 0.33%, Britain\’s FTSE 100 index fell 0.4%, and Europe\’s Stoxx 50 index fell 0.34%.

    stock options May 21, 2024
  • Hatsun Agro Product’s shares surge 11.17% on quarterly results

    Hatsun Agro Product Ltd’s shares were up by 11.17 per cent after the company reported its financial results for the fourth quarter and the financial year ending March 31, 2024. In Q4 FY24, the company saw a revenue growth of 14.38%, with revenue from operations reaching ₹2046.87 crore compared to last year when the company reported ₹1789.46 crore. The EBITDA grew by 46.64% to ₹231.77 crore, and the Profit after tax (PAT) increased by 108% to ₹52.16 crore compared to Q4 FY23 where it stood at ₹24.98 crore

    stock options April 23, 2024
  • Stocks that will see action today May 6, 2024

    Paytm’s parent company One97 Communications president and chief operating officer Bhavesh Gupta has resigned from the company, an official statement said. Gupta steered the lending business, online and offline payments, and compliances, at Paytm. Verticals, headed by him were adversely impacted by the RBI’s ban on Paytm Payments Bank (PPBL) from carrying on new transactions.

    stock options May 7, 2024
  • Eurozone PMI data is encouraging, economy is gathering momentum

    Gelonghui, May 23 | Cyrusdela Rubia, chief economist of Hamburg Commerzbank, said that today’s Eurozone data couldn’t look better.

    stock options May 23, 2024
  • Beite Technology: Net profit in the first quarter of 2024 was 16.4353 million yuan, a year-on-year increase of 183.06%

    CSI Intelligent Financial Information Beite Technology (Weight Protection) (603009) disclosed its first quarter report for 2024 on April 26. In the first quarter of 2024, the company achieved total operating income of 490 million yuan, a year-on-year increase of 25.97%; net profit attributable to the parent company was 16.4353 million yuan, a year-on-year increase of 183.06%; non-net profit after deducting 14.7083 million yuan, a year-on-year increase of 282.15%; generated from operating activities Net cash flow was -42.8616 million yuan, compared with 33.144 million yuan in the same period last year; during the reporting period, Beite Technology\’s basic earnings per share was 0.0458 yuan, and the weighted average return on net assets was 1.02%.

    stock options April 25, 2024